Claim Details

View detailed information about this claim and its related sources.

Back to Claims

Claim Information

Complete details about this extracted claim.

Claim Text
Philip Castle, the director of the cancer prevention division at the N.C.I., said during the meeting that the test’s ability to detect cancers in the early stages, “where intervention matters the most, remains poor.”
Simplified Text
Philip Castle, director of the NCI's cancer prevention division, said during the FDA advisory meeting that the Galleri test's ability to detect early-stage cancers 'remains poor'.
Confidence Score
1.000
Claim Maker
Philip Castle
Context Type
News Article
Context Details
{
    "date": "2026-09-23",
    "event": "FDA advisory committee meeting",
    "person": "Philip Castle",
    "organization": "National Cancer Institute"
}
Subject Tags
Health Regulation Cancer
UUID
7902524e-169c-425b-813f-0c2600eaf882
Vector Index
✗ No vector
Created
September 25, 2026 at 1:05 AM (2 weeks ago)
Last Updated
September 25, 2026 at 1:05 AM (2 weeks ago)

Original Sources for this Claim (1)

All source submissions that originally contained this claim.

Screenshot of https://nytimes.com/2026/09/23/well/fda-cancer-blood-test-galleri-grail.html
F.D.A. Advisory Panel Endorses Controversial Cancer Blood Test
Completed News
5 claims
2 weeks ago
https://nytimes.com/2026/09/23/well/fda-cancer-blood-test-galleri-grail.html

An FDA advisory committee recommended approval for Grail's Galleri blood test, designed to detect various cancers early, despite concerns from doctors about its efficacy and lack of data showing reduced cancer deaths. The test has been available since 2021, but experts warn of risks like overdiagnosis and false positives.

FDA Cancer Screening Blood Tests Medical Technology Health Policy Oncology Grail Galleri

Similar Claims (5)

Other claims identified as semantically similar to this one.